Technical Analysis for DAWN - Day One Biopharmaceuticals, Inc.
| Grade | Last Price | % Change | Price Change |
|---|---|---|---|
| A | 17.57 | -0.68% | -0.12 |
DAWN closed down 0.68 percent on Thursday, May 2, 2024, on 61 percent of normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions. Note that the stock is in overbought territory based on its Slow Stochastic indicator (14, 3, 3) -- so don't be surprised if it goes sideways or a pulls back.
Earnings due: May 9
*** please verify all earnings dates ***| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | Up | Up | Up |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| NR7 | Range Contraction | 0.00% | |
| Upper Bollinger Band Walk | Strength | 0.00% | |
| Inside Day | Range Contraction | 0.00% | |
| Wide Bands | Range Expansion | 0.00% | |
| Overbought Stochastic | Strength | 0.00% | |
| Upper Bollinger Band Touch | Strength | 0.00% | |
| New 52 Week Closing High | Bullish | -0.68% | |
| Calm After Storm | Range Contraction | -0.68% | |
| New 52 Week High | Strength | -0.68% | |
| Stochastic Reached Overbought | Strength | -0.68% |
| Alert | Time |
|---|---|
| Possible NR7 | about 10 hours ago |
| Possible Inside Day | about 10 hours ago |
| Down 3% | about 13 hours ago |
| Down 2 % | about 14 hours ago |
| Down 1% | about 14 hours ago |
Get this analysis on your stocks daily!
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 05/09/2024
Day One Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genetically defined cancers. Its lead product candidate is DAY101, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/progressive low-grade glioma. The company is also developing Pimasertib, an oral small molecule inhibitor of mitogen-activated protein kinase kinases 1 and 2. Day One Biopharmaceuticals, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.
Sector: Healthcare
Industry: Biotechnology
Keywords: Biopharmaceutical Cancer Enzymes Protein Kinase Inhibitor Signal Transduction Protein Kinase Kinase Ym Biosciences
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Biopharmaceutical Cancer Enzymes Protein Kinase Inhibitor Signal Transduction Protein Kinase Kinase Ym Biosciences
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 18.0699 |
| 52 Week Low | 9.67 |
| Average Volume | 1,183,870 |
| 200-Day Moving Average | 13.67 |
| 50-Day Moving Average | 15.37 |
| 20-Day Moving Average | 15.17 |
| 10-Day Moving Average | 15.91 |
| Average True Range | 1.21 |
| RSI (14) | 60.47 |
| ADX | 22.44 |
| +DI | 32.59 |
| -DI | 14.88 |
| Chandelier Exit (Long, 3 ATRs) | 14.44 |
| Chandelier Exit (Short, 3 ATRs) | 16.65 |
| Upper Bollinger Bands | 17.71 |
| Lower Bollinger Band | 12.62 |
| Percent B (%b) | 0.97 |
| BandWidth | 33.58 |
| MACD Line | 0.51 |
| MACD Signal Line | 0.17 |
| MACD Histogram | 0.3335 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 18.91 | ||||
| Resistance 3 (R3) | 18.88 | 18.41 | 18.68 | ||
| Resistance 2 (R2) | 18.41 | 18.07 | 18.42 | 18.61 | |
| Resistance 1 (R1) | 17.99 | 17.86 | 17.76 | 18.02 | 18.53 |
| Pivot Point | 17.52 | 17.52 | 17.40 | 17.53 | 17.52 |
| Support 1 (S1) | 17.10 | 17.18 | 16.87 | 17.13 | 16.61 |
| Support 2 (S2) | 16.63 | 16.97 | 16.64 | 16.53 | |
| Support 3 (S3) | 16.21 | 16.63 | 16.46 | ||
| Support 4 (S4) | 16.24 |
